Immunogenicity, safety and tolerability of monovalent 2009 pandemic influenza A/H1N1 MF59-adjuvanted vaccine in patients with β-thalassemia major

Susanna Esposito, Emanuela D'Angelo, Cristina Daleno, Francesco Peia, Alessia Scala, Domenico Serra, Nadia Mirra, Carlotta Galeone, Nicola Principi

Research output: Contribution to journalArticlepeer-review

Abstract

In order to evaluate the immunogenicity, safety, and tolerability of monovalent 2009 pandemic influenza A/H1N1 MF59-adjuvanted vaccine in patients with β-thalassemia major, 31 subjects (19 males; mean age 17.8 ± 8.7 years) with β-thalassemia major and 28 age- and gender-matched healthy controls were enrolled. Four weeks after vaccination, seroconversion rates were about 80% and seroprotection rates 100% in both groups. Three months after vaccination, most of the subjects remained seroconverted and the seroprotection rates were 93.5% among the patients and 100% among the controls. Safety and tolerability were also very good, with no differences between the groups.

Original languageEnglish
Pages (from-to)7825-7828
Number of pages4
JournalVaccine
Volume28
Issue number50
DOIs
Publication statusPublished - Nov 23 2010

Keywords

  • Adjuvants
  • Children
  • MF59
  • Pandemic A/H1N1 influenza virus
  • Pandemic influenza A/H1N1 influenza vaccine
  • Vaccination

ASJC Scopus subject areas

  • Molecular Medicine
  • Immunology and Microbiology(all)
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)

Fingerprint Dive into the research topics of 'Immunogenicity, safety and tolerability of monovalent 2009 pandemic influenza A/H1N1 MF59-adjuvanted vaccine in patients with β-thalassemia major'. Together they form a unique fingerprint.

Cite this